Bracco Diagnostics Inc. launched its Bracco Mobile Isotope Service (BMIS) program in 2021 to address this and other challenges to offering cardiac PET imaging for patients. The service provides ...
The US Food and Drug Administration (FDA) has granted fast track designation for the development of Bracco Imaging's molecular imaging ultrasound contrast agent, BR55, to identify active bowel ...
Bracco Diagnostics is a leader in cardiac PET, and its premier solutions have become essential tools for physicians making treatment decisions for cardiac disease. Since its launch in 1989 ...
Vietnam Investment Review on MSN14d
THE BRACCO GROUP: OFFICIAL GOLD SPONSOR OF THE ITALY PAVILION AT THE OSAKA EXPO 2025
The Commissioner General for Italy at Expo 2025 Osaka, Ambassador Mario Vattani, and Diana Bracco, President and CEO of the Bracco Group, ...
The two companies announced the launch of a study to reduce contrast media in wastewater through sustainable urine filtration systems for hospitals and diagnostic facilities MILAN, Feb. 26, 2025 ...
The company is currently preparing for Phase III trials to further assess the efficacy and safety of the agent in identifying active inflammation in individuals with Crohn's disease. Credit ...
"As a leader in medical imaging, Bracco recognizes that sustainability and innovation must go hand in hand and we are motivated by a responsibility to drive meaningful change," said Erik Bruno ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results